Saydam Guray, Unal Ali, Haznedaroglu Ibrahim Celalettin, Hacihanifioglu Abdullah, Mehtap Ozgur, Kurtoglu Erdal, Gocer Mesut, Turgut Mehmet, Kelkitli Engin, Atay Memis Hilmi, Guler Nil, Koluman Basak Unver, Sonmez Mehmet, Erkut Nergiz, Kaya Emin, Kuku Irfan, Erkurt Mehmet Ali, Ozet Gulsum, Ceran Funda, Sahin Fahri, Soyer Nur, Nalcaci Meliha, Yilmaz Mehmet, Bozkurt Sirac, Aver Birkan, Ozdengulsun Begum, Ozbilgili Egemen, Ilhan Osman
Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey.
Department of Internal Diseases, Division of Hematology, Erciyes University Faculty of Medicine, Kayseri, 38030, Turkey.
Int J Hematol Oncol. 2022 Jun 30;11(3):IJH40. doi: 10.2217/ijh-2021-0008. eCollection 2022 Jun.
This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.
MATERIALS & METHODS: Hospital records between 2005 and 2018 were retrospectively reviewed.
Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.
The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
本研究旨在确定土耳其慢性期（CP）-慢性髓性白血病（CML）患者的特征、治疗模式和结局，并评估诊断时合并症的存在对其的影响。
对2005年至2018年期间的医院记录进行回顾性分析。
在纳入的861例CP-CML患者中，31%在诊断时有至少一种合并症。性别、诊断时的心血管疾病状况以及分子（至少主要）和细胞遗传学（部分和完全）反应是生存的独立预测因素。
CP-CML患者对酪氨酸激酶抑制剂的反应率令人满意。在CML患者的治疗选择中，除了药物的耐受性和副作用情况外，还应考虑患者的合并症状况。
